作者: Chih-Yi Hsu , Hsiang-Ling Ho , Shih-Chieh Lin , Ming-Hsiung Chen , Sanford P-C. Hsu
DOI: 10.1097/PAI.0000000000000331
关键词:
摘要: The O-methylguanine-DNA-methyltranferase (MGMT) status is a powerful predictor of response to temozolomide for newly diagnosed glioblastoma (GBM) patients, and it commonly assessed by immunohistochemistry (IHC), methylation-specific polymerase chain reaction (MSP), quantitative real-time MSP (qMSP), and/or pyrosequencing (PSQ). This study was compare their predictive power prognosis in 121 GBM patients using multivariate Cox regression with bootstrapping. MGMT tested IHC, MSP, qMSP, or PSQ all showed significant correlation the progression-free survival overall patients. IHC lower than those methylation assays, but differences were not significant. Performing additional assay, especially PSQ, could better predict IHC- tumors. prognostic significance. An which appeared be best, improve